Acrivon Therapeutics (ACRV) Cash Flow: Operating & Free Cash Flow

Acrivon Therapeutics Cash Flow Statement Analysis

Values in millions USD

Income Statement Balance Sheet Cash Flow Ratios

Scale:

Scroll to see more

Cash flow statement showing operating, investing, and financing activities for Acrivon Therapeutics, Inc. (ACRV) - Annual data in millions USD
Breakdown	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period ending	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Operating Activities
Net Income	-77.91	-80.56	-60.39	-31.17	-16.24	-5.31
Depreciation & Amortization	0.92	1.01	0.54	0.36	0.04	0.01
Deferred Income Tax	0.00	0.00	-3.61	0.00	0.00	0.00
Stock Based Compensation	14.72	14.29	11.62	2.19	0.50	0.00
Change in Working Capital	-2.43	2.44	8.14	-1.53	0.33	0.32
Change in Accounts Payable	1.54	-3.59	3.61	-0.25	0.80	0.08
Change in Other Working Capital	-3.96	-2.00	1.36	-4.21	1.14	0.24
Other Operating Activities	1.03	-2.85	-2.55	0.03	1.14	2.17
Net Cash from Operating Activities	-63.67	-65.67	-42.64	-30.12	-13.98	-2.80
Investing Activities
Capital Expenditures	-1.67	-2.77	-1.29	-2.17	-0.24	-0.02
Purchases of Investments	-81.73	-202.93	-56.53	-150.18	0.00	0.00
Sales/Maturities of Investments	149.50	153.92	108.53	10.67	0.00	0.00
Net Cash from Investing Activities	66.10	-51.77	50.72	-141.68	-0.24	-0.02
Financing Activities
Debt Repayment	0.00	0.00	0.00	0.00	0.00	0.06
Common Stock Issued	0.00	130.09	0.78	104.48	0.00	0.00
Common Stock Repurchased	0.00	-2.52	-1.30	0.00	0.00	0.00
Other Financing Activities	-0.75	53.46	-1.03	-2.77	112.22	2.83
Net Cash from Financing Activities	-0.75	121.03	-1.55	101.71	112.22	2.89
Summary
Net Change in Cash	1.69	3.59	6.52	-70.08	98.00	0.07
Cash at Beginning of Period	40.02	36.43	29.91	99.99	1.99	1.92
Cash at End of Period	41.70	40.02	36.43	29.91	99.99	1.99
Free Cash Flow	-65.33	-68.44	-43.93	-32.28	-14.22	-2.82

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Acrivon Therapeutics Cash Flow

What is Acrivon Therapeutics's free cash flow?

Acrivon Therapeutics had negative free cash flow of $65.33M in fiscal 2025 (fiscal year ended Dec 31, 2025), operating cash flow of −$63.66M minus $1.67M of capital expenditures.

How much does Acrivon Therapeutics spend on capital expenditures?

Acrivon Therapeutics spent $1.67M on capital expenditures in fiscal 2025, compared with $2.77M a year earlier.

Does Acrivon Therapeutics pay dividends or buy back shares?

Acrivon Therapeutics's cash flow statement for fiscal 2025 shows no dividend payments or share repurchases.

What is free cash flow?

Free cash flow is operating cash flow minus capital expenditures. It is the cash a company has left for dividends, buybacks, debt repayment or acquisitions after funding its operations and investment. Full definition